公开(公告)号：US11548941B2

公开(公告)日：2023-01-10

申请号：US16688178

申请日：2019-11-19

Applicant: Janssen Biotech, Inc.

Inventor： Julianty Angsana ,  Patrick Branigan ,  Samuel DePrimo ,  Susan Flavin ,  Shu Li ,  Xuejun Liu ,  Ernesto Munoz ,  Bruce Randazzo

IPC: C07K16/24 ,  A61K39/395 ,  A61P17/06 ,  A61K45/06

Abstract: A method of treating psoriasis in a patient by administering an IL-23 specific antibody, e.g., guselkumab, in a clinically proven safe and clinically proven effective amount and the patient achieves PASI90, PASI100 or IGA 0 or 1 score as measured 16, 24, 32, 40 and 48 weeks after initial treatment and the patient achieves higher efficacy than a patient treated with the secukinumab antibody.

公开(公告)号：US20220289835A1

公开(公告)日：2022-09-15

申请号：US17734482

申请日：2022-05-02

Applicant: Janssen Biotech, Inc.

Inventor： Julianty Angsana ,  Patrick Branigan ,  Samuel DePrimo ,  Susan Flavin ,  Shu Li ,  Xeujun Liu ,  Ernesto Munoz ,  Bruce Randazzo

IPC: C07K16/24 ,  A61P17/06 ,  A61K39/395

Abstract: A method of treating psoriasis in a patient by administering an IL-23 specific antibody, e.g., guselkumab, in a clinically proven safe and clinically proven effective amount and the patient achieves PASI90, PASI100 or IGA 0 or 1 score as measured 16, 24, 32, 40 and 48 weeks after initial treatment and the patient achieves higher efficacy than a patient treated with the secukinumab antibody.

公开(公告)号：US20200157209A1

公开(公告)日：2020-05-21

申请号：US16688178

申请日：2019-11-19

Applicant: Janssen Biotech, Inc.

Inventor： Julianty Angsana ,  Patrick Branigan ,  Samuel DePrimo ,  Susan Flavin ,  Shu Li ,  Xuejun Liu ,  Ernesto Munoz ,  Bruce Randazzo

IPC: C07K16/24 ,  A61P17/06

Abstract: A method of treating psoriasis in a patient by administering an IL-23 specific antibody, e.g., guselkumab, in a clinically proven safe and clinically proven effective amount and the patient achieves PASI90, PASI100 or IGA 0 or 1 score as measured 16, 24, 32, 40 and 48 weeks after initial treatment and the patient achieves higher efficacy than a patient treated with the secukinumab antibody